

NEKTAR THERAPEUTICS  
Form 8-K  
November 03, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): November 3, 2016**

**NEKTAR THERAPEUTICS**  
**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**0-24006**  
**(Commission**  
  
**File Number)**  
**455 Mission Bay Boulevard South**

**94-3134940**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K

**San Francisco, California 94158**

**(Address of Principal Executive Offices and Zip Code)**

**Registrant's telephone number, including area code: (415) 482-5300**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition.**

On November 3, 2016, Nektar Therapeutics, a Delaware corporation ( Nektar ), issued a press release (the Press Release ) announcing its financial results for the quarter ended September 30, 2016. A copy of the Press Release is furnished herewith as Exhibit 99.1.

On October 27, 2016, Nektar announced that it would hold a Webcast conference call on November 3, 2016 to review financial results for the quarter ended September 30, 2016. This conference call is accessible through a link that is posted on the home page and Investor Relations section of the Nektar website: <http://www.nektar.com>.

The information in this report, including the exhibit hereto, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**Item 9.01 Financial Statements and Exhibits.**

**Exhibit**

**Number**

**Description**

99.1	Press Release titled Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016 issued by Nektar Therapeutics on November 3, 2016.
------	---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NEKTAR THERAPEUTICS**

November 3, 2016

By: */s/ Mark A. Wilson*  
Mark A. Wilson  
*Vice President and General Counsel*

**EXHIBIT INDEX**

**Exhibit  
No.**

**Description**

99.1 Press Release titled Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016 issued by Nektar Therapeutics on November 3, 2016.